Updated Jul 16, 2026
BERGER FRANKLIN M has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $1.02M.

Franklin M. Berger is a seasoned executive and board member in the biotechnology sector, known for his roles in various pharmaceutical companies. He has served as a director for Kezar Life Sciences, Inc., ESSA Pharma Inc., and Atea Pharmaceuticals, Inc., contributing his expertise in corporate governance and strategic oversight.
| Role | Insider |
|---|---|
| Notability | 75/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-23 | AVIR | Atea Pharmaceuticals, Inc. | M — Option exercise | 29.6K | $0.00 | |
| 2026-05-11 | KZR | Kezar Life Sciences, Inc. | J — Other acquisition / disposition | 89.1K | — | |
| 2025-10-09 | EPIX | ESSA Pharma Inc. | D — Derivative transaction | 784.4K | — | |
| 2025-06-20 | AVIR | Atea Pharmaceuticals, Inc. | M — Option exercise | 29.6K | $0.00 | |
| 2024-12-12 | AVIR | Atea Pharmaceuticals, Inc. | S — Open-market sale | 359.6K | $2.85 | $1.02M |
Franklin M. Berger is a seasoned executive and board member in the biotechnology sector, known for his roles in various pharmaceutical companies. He has served as a director for Kezar Life Sciences, Inc., ESSA Pharma Inc., and Atea Pharmaceuticals, Inc., contributing his expertise in corporate governance and strategic oversight.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($1.02M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live BERGER FRANKLIN M profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.